Inozyme Pharma, Inc. (INZY)

NASDAQ: INZY · IEX Real-Time Price · USD
3.03
+0.27 (9.78%)
Mar 21, 2023, 3:59 PM EDT - Market closed
9.78%
Market Cap 127.07M
Revenue (ttm) n/a
Net Income (ttm) -67.27M
Shares Out 41.80M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 837,722
Open 2.76
Previous Close 2.76
Day's Range 2.76 - 3.18
52-Week Range 0.99 - 6.25
Beta 0.79
Analysts Buy
Price Target 19.46 (+542.24%)
Earnings Date Mar 21, 2023

About INZY

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is he... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 50
Stock Exchange NASDAQ
Ticker Symbol INZY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for INZY stock is "Buy." The 12-month stock price forecast is $19.46, which is an increase of 542.24% from the latest price.

Price Target
$19.46
(542.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Earnings Season Could Be Great for Inozyme (INZY)

Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 days ago - Zacks Investment Research

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mi...

2 weeks ago - GlobeNewsWire

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial -

1 month ago - GlobeNewsWire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) –

1 month ago - GlobeNewsWire

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 –

2 months ago - GlobeNewsWire

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate -

3 months ago - GlobeNewsWire

Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

3 months ago - GlobeNewsWire

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 –

4 months ago - GlobeNewsWire

Inozyme Pharma to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic min...

4 months ago - GlobeNewsWire

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

- Peer-reviewed article in Human Mutation reports 3-fold increase in pathogenic/likely pathogenic ENPP1 variants –

5 months ago - GlobeNewsWire

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t...

7 months ago - GlobeNewsWire

Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency –

7 months ago - GlobeNewsWire

Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...

8 months ago - GlobeNewsWire

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of INZ-...

8 months ago - Benzinga

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) –

8 months ago - GlobeNewsWire

How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

9 months ago - Zacks Investment Research

Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually New technology aims to expand testing to approximately 1,000 diseases and sequenci...

9 months ago - GlobeNewsWire

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...

10 months ago - GlobeNewsWire

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal miner...

10 months ago - GlobeNewsWire

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency –

11 months ago - GlobeNewsWire

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, tod...

11 months ago - GlobeNewsWire

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mine...

1 year ago - GlobeNewsWire

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial...

1 year ago - Benzinga

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency –

1 year ago - GlobeNewsWire

Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, t...

1 year ago - GlobeNewsWire